AstraZeneca acquires biologics manufacturing facility in Canada

Published: 4-Jun-2007
Media Ingredients Pharmaceutical

AstraZeneca has acquired a biologics manufacturing facility in Montreal, Canada, from DSM Biologics.


AstraZeneca has acquired a biologics manufacturing facility in Montreal, Canada, from DSM Biologics.

The 66,000ft2 facility, will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group.

'This is a further step in our global plan to accelerate the delivery of promising pre-clinical biopharmaceutical candidate drugs into our development portfolio,' said Dr John Patterson, AstraZeneca's executive director, development. 'It extends the set of supply capabilities we have assembled through MedImmune and Cambridge Antibody Technology (CAT) and takes advantage of the biotechnology skills in Quebec.'

Work will now start to recommission the facility, and the company plans to commence full-scale production in 2009.

'Ultimately, this investment will help strengthen our pipeline by building a larger portfolio of biological drugs,' added Mark Jones, president and ceo, AstraZeneca Canada.

  • Companies:
  • AstraZeneca
See more

You may also like

Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

Read more
The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Rousselot Biomedical launches EU MDR compliant gelatin range From May 2024, all devices placed on the European market must conform with the EU Medical Device Regulation (MDR)
  3. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  4. Lessons learned: AstraZeneca’s supply chain resilience during the pandemic With 26 manufacturing facilities and a global network of more than 250 suppliers, AstraZeneca’s Global Operations Manufacturing footprint is not only large in scale, it's also highly complex and positioned to deliver medicines to patients worldwide
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Regulatory

AstraZeneca’s Tagrisso plus chemo for EGFR-mutated lung cancer approved in Japan

The approval comes off the back of the positive Phase III FLAURA2 trial results, showing a significant improvement in PFS compared with Tagrisso monotherapy
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Nanoform grants Global STARMAP AI License to AstraZeneca

Nanoform Finland, an innovative nanoparticle medicine-enabling company has announced that it has granted AstraZeneca Plc a global online STARMAP licence
Subscribe now